MedTrace Logo

Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients

NCT01017172 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2009-11-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the immunogenicity and safety of an adjuvanted A(H1N1)v influenza vaccine in HIV-infected and immunosuppressed patients after one and two injections.

Conditions

  • HIV-1 Infection
  • Cancer
  • Immunosuppression

Interventions

OTHER

serologic testing

Serologic testing will be performed baseline, day 21 and day 42

Sponsors & Collaborators

  • HIVCENTER

    collaborator UNKNOWN

  • Goethe University

    lead OTHER

Principal Investigators

  • Markus Bickel, MD · JW Goethe University Clinic

  • Christoph Stephan, MD · JW Goethe University Clinic

  • Hans R Brodt, MD · JW Goethe University Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01017172 on ClinicalTrials.gov